INTRODUCTION
Very low birth weight (VLBW) infants are vulnerable to hypotension and its associated clinical complications, such as intraventricular hemorrhage (IVH), 1, 2 necrotizing enterocolitis, and exacerbation of respiratory distress syndrome. 3 In response to hypotension, vasopressors are used to raise blood pressure (BP) and to increase cardiac contractility. 4 -9 Birth weight and gestational age have been shown to be strong correlates of systolic and diastolic BPs. 10 Several authors have shown that infants who develop IVH had lower mean BP 1, 2 and have postulated a mechanism of poor cerebral vascular autoregulation. Studies have provided evidence of associations among BP, cerebral blood flow, pulsatility index, and risk of IVH. 2,11 -14 This pulsatility hypothesis suggests that higher BPs may also be dangerous.
Another factor which may interact with hypotension in the development of IVH is presence of a patent ductus arteriosus (PDA). 15, 16 Indomethacin administration reportedly decreases the mean blood flow velocity of the anterior cerebral arteries. 17 -19 Indomethacin may reduce the likelihood of IVH by stabilizing cerebral blood flow. In addition, PDA closure results in an increase in the average mean BP. 20 There are risks of indomethacin treatment for PDA closure, however. 21, 22 Despite the potential severe consequences of low BP, no widely accepted neonatal BP standard has been defined. 3, 10, 28, 29 This lack of agreement on definitions for hypotension and hypertension in the premature baby may lead to marked differences in the treatment threshold for ''abnormal'' BP.
We evaluated differences in the prevalence of hypotension and hypertension among six NICUs in an ongoing study of variations in outcomes of VLBW newborns. We reasoned that differences in the occurrence of hypotension and hypertension might reflect differences in clinical practices and treatment strategies in the six NICUs. The differing strategies in turn could constitute an arbitrary, and in effect a ''quasi-random,'' allocation either to relatively more or less aggressive management of BP. Fair comparisons could be achieved
OBJECTIVE:
Very low birth weight infants are vulnerable to hypotension and its associated complications. Vasopressors are used to raise blood pressure ( BP ) , but indications for use are uncertain. Our objectives were ( 1 ) to study variations in BP stability among NICUs, ( 2 ) to investigate inter -NICU differences in vasopressor use, and ( 3 ) to address the association between intraventricular hemorrhage ( IVH ) and abnormal BPs.
STUDY DESIGN:
A total of 1288 infants with birth weight < 1500 g were admitted to six NICUs in Massachusetts and Rhode Island over 21 months. The lowest and highest mean BPs were collected within the first 12 hours. Also recorded were the use of vasopressors within the first 24 hours and the occurrence of IVH. Logistic regressions were used to model outcomes, controlling for gestational age and illness severity using the Score for Neonatal Acute Physiology.
RESULTS:
Two of the six NICUs had significantly higher percentages of infants with at least one hypotensive BP, with prevalences of 24% to 45%. Percentages of infants treated with vasopressors ranged from 4% to 39%. This range of vasopressor use could not be explained by inter -NICU differences in birth weight, illness severity, or rates of hypotension. We found a borderline association between severe IVH and hypotension ( odds ratio 1.6, p = 0.055 ) , but not between severe IVH and hypertension. Readmissions and outborns admitted after 24 hours of life were excluded (n=91) to ensure homogeneity of the population. Records with missing information on vasopressor use (n=49) and PDA treatment (n=35) were also excluded, resulting in a final sample size of 1288.
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Data Collection
Data abstraction was performed prospectively in the NICUs using laptop computers. Extensive training and customized data entry software providing error checking and explicit definitions ensured uniformity at all sites. Medical records review was approved by the institutional review boards at all six hospitals. For confidentiality, sites are labeled A to F. The range of number of patients was 146 to 335. The number of infants from each NICU is not indicated, as this would reveal site identity.
Definitions
Birth weight groups. Infants were grouped into three birth weight groups: <750 g (n=276), !750 g but <1000 g (n=327), and !1000 g but <1500 g (n=685).
Illness severity. The Score for Neonatal Acute Physiology (SNAP) recorded over the first 12 hours of admission was used as the measure of illness severity. 31 SNAP objectively assesses the degree of illness using several physiologic measures in each organ system derived from routine vital signs and laboratory values. Points are assigned according to the degree of derangement and then summed to yield the final score; a high SNAP indicates a sick baby. SNAP has been shown to be a highly significant predictor of morbidity and mortality. 32 To differentiate between a high SNAP score due to an abnormal BP and that due to another failing system, we defined an additional variable, SNAP-BP, which is the SNAP score excluding the BP subscore. Illness severity was divided into three categories, high (SNAP !20; n=146), moderate (10 to 19; n=520), and low (0 to 9; n=618). Four records had missing SNAP.
BP. BP values obtained by either cuff (Dinamap) or arterial catheter were collected from the patient flowsheets from the first 12 hours of admission. To account for both the systolic as well as the diastolic components, we collected the mean BP. In the few cases where only systolic and diastolic BPs were recorded, the mean BP was calculated using the formula: [Diastolic BP+1/3(Systolic BPÀDiastolic BP) =Mean BP]. Only the lowest and highest values were abstracted as part of the scoring procedure for SNAP. These extreme lowest and highest values were used to classify the occurrence of hypotension and hypertension. Mean BP and 95% confidence intervals (CI) were extrapolated for birth weights below the 750 g using published data. 29 All values falling within the 95% CI were categorized ''within standard,'' whereas those outside of this range were classified as above or below standard. The resulting BP ranges are extremely generous, classifying a wide range of ''within standard.'' For example, a baby of 1000 g birth weight would need to have a mean BP below 24 mm Hg to be classified as hypotensive. In contrast, Tan 30 found higher mean arterial BP ranges on the first day in healthy infants with birth weight <1500 g, 57.7 mm Hg ( ±2 SD 31.8 mm Hg) during the awake state and 55.8 mm Hg ( ±2 SD 27.2 mm Hg) during sleep. We also employed a data-derived BP Z score (i.e., a relative percentile) at each gestational age to compare with published standards. The BP distribution in our study population was divided into four quartiles. Because these results were similar to the data of Versmold et al., 29 that standard was chosen for our comparisons.
Vasopressors. Vasopressor information was collected from the patient flowsheets and medication sheets. Administration of any vasopressors within the first 24 hours of admission was noted in addition to the number of drugs used, and recorded as one drug versus two or more. The times and doses of the medications were not recorded. Epinephrine was coded as a vasopressor, unless it was administered in the course of cardiopulmonary resuscitation.
Therapeutic intensity and outcomes. We recorded the checklist of other intensive care therapies included in the Neonatal Therapeutic Intervention Scoring System, 33 which contains subscores for respiratory support, medications, cardiac and respiratory monitoring, intravascular catheters, and transfusions used in the first 24 hours of admission.
Outcomes collected included IVH and vital status at discharge. Ultrasound readings were abstracted from the records and the occurrence of IVH was classified by the highest Papile grade. 34 The ascertainment of PDA differed by site, and ranged from detection of clinical signs to routine echocardiography. Therefore, we recorded the decision to treat a PDA with indomethacin as an indicator of the presence of a clinically significant PDA. At one site (site A), there was a policy of routine indomethacin prophylaxis within the first 6 hours for infants <1250 g birth weight. Hence, in order to avoid miscoding, we defined therapeutic treatment as indomethacin administration after the first 24 hours (n=256, 19.3%) or treatment followed by surgical ligation of the PDA (n=35, 2.6%); few patients had surgical ligation in the absence of prior medical therapy (n=9, 0.7%).
Statistical Analysis
The Statistical Analysis System (SAS Corporation, Cary, NC) was used for data analysis and management. For univariate analyses, t tests and -squared analysis were employed. Multivariate methods included logistic regression in which one site was designated as reference, and dummy variables were employed for the remaining sites. The reference site was selected based on its sample size and, therefore, its statistical stability as a reference point. Logistic regressions were used to predict the occurrence of hypotensive versus non-hypotensive values using the standards of Versmold et al. 29 Hypotension was modeled as a function of antenatal corticosteroid use and gender, adjusted for illness severity and maturity. Logistic regressions were used to model vasopressor use as a function of hypotension, SNAP-BP, gestational age, antenatal corticosteroids, and gender. Logistic regressions were also used to model severe IVH (grades III to IV) as a function of hypotension and nonprophylactic indomethacin, adjusted for maturity, illness severity, and demographic and therapeutic risk factors.
RESULTS

Population
The sites A to F are ordered according to the incidence of vasopressor usage ranging from lowest use at site A to highest use at site F. This ranking facilitates identification of other factors associated with vasopressor use, which may follow a similar ranking. The population in each of the six NICUs is described in Table 1 . Population risk differed significantly among the NICUs. Sites A and B had higher proportions of the smallest babies ( <750 g) and sick babies (SNAP>20), whereas sites C, E, and F had the lowest proportion of the sickest babies. Sites A and B had the highest proportion of babies with 5-minute Apgar scores <7. Sites A and B also administered antenatal corticosteroids less frequently than the other sites.
Standard and Non-Standard Mean BP In Table 2 , for the entire study population, we compare infants with at least one hypotensive BP versus those whose BPs all remained within the standard range. Hypotensive infants were significantly smaller, younger, and sicker. The mean lowest recorded mean BP was 10 mm Hg lower for the hypotensive group. By contrast, the infants found to have at least one hypertensive BP did not differ from the normotensive group in birth weight and illness severity. However, hypertensive infants were, on average, a half week younger in (Table 3) . Comparable results were seen when the entire group was divided into quartiles using our BP Z score. The ranking of the sites by incidence of hypotension followed a similar order when ranked using data-driven quartiles as when the standards of Versmold et al. were used. Sites C and D had the highest incidence of BPs in the lowest quartile (37% and 33%, respectively) versus sites A, B, E, and F (17%, 20%, 15%, and 20%, respectively). Table 3 presents the unadjusted vasopressor usage in the six sites, where the sites A to F are listed in ascending order of usage. These nine-fold differences in rates are highly significant (p<0.0001), ranging from 4.3% at site A to 39.0% at site F. Intravascular volume expansion is often used as an alternative measure to support BP. However, because the rank order of sites for volume expansion and vasopressor use is similar, it appears that volume expanders were used as adjuncts to, rather than substitutes for, vasopressor administration. There is no concordance between the prevalence of vasopressor use and the incidence of hypotension across NICUs. This may reflect specific NICU preferences for pro-active versus reactive strategies (i.e., treating before occurrence of hypotension, thereby reducing incidence versus avoidance of vasopressor use unless hypotension occurs). It would appear that sites E and F have a more liberal threshold for vasopressor use.
Differences in Use of Vasopressors and Associated Treatments
In regard to other treatments that may be associated with BP stability, it is interesting to note that the two sites with the highest rates of hypotensive mean BP (sites C and D) were two of three sites where indomethacin is rarely administered within the first 24 hours. However, site E showed little early use of indomethacin, but had the second lowest incidence of hypotension. Similarly, frequent use of antenatal corticosteroids might be expected to be correlated with a lower incidence of hypotension. We found no consistent relationship. Sites C and D have high rates of administering a complete course of antenatal corticosteroids (49.6% and 56.4%, respectively) ( Table 1) compared to 40.9% and 41.7% antenatal corticosteroid administration at sites A and B, which had lower rates of hypotension among these VLBW infants.
The incidence of hypertensive BPs, however, follows a very similar rank order to that of vasopressor use, suggesting that hypertension may be a side effect of vasopressors or that a higher target BP is being used. Site A administered vasopressors least frequently and had the lowest rate of hypertensive BPs, whereas site F administered vasopressors most frequently and had the highest rates of hypertensive BPs. The differences in incidence of hypertension are highly significant (p<0.001) and appear to reflect differences in practice style among the NICUs.
Multivariate Models of Hypotension, Vasopressor Use, and IVH
The three multivariate logistic models presented in Table 4 predict the occurrence of hypotensive mean BP, vasopressor use, and severe IVH (grades III to IV). In all three models, gestational age was a more significant factor than birth weight and was therefore used preferentially to avoid collinearity.
When predicting the occurrence of at least one hypotensive mean BP, SNAP-BP, GA, and antenatal corticosteroids proved to be powerful independent predictors. Each additional five SNAP points increased the odds of hypotension by 20% and, for each advancing week of gestation, there was a 20% decrease in the odds of hypotension. Antenatal corticosteroids reduced a baby's likelihood of being hypotensive by 26%. Being male increased the risk of hypotension by 30%. We included the presence of an arterial line to control for potential differences in ascertainment of hypotension by cuff versus indwelling arterial line. Finally, as suggested by the crude data in Table 3 , we confirmed that sites C, D, and F show significantly higher risk-adjusted odds of hypotensive pressures compared to site E.
For predicting vasopressor use, having a hypotensive mean BP proved to be the most important predisposing factor. A higher SNAP-BP score and being male also increased the odds of receiving vasopressors. The odds ratios (ORs) for vasopressor use among the sites follow nearly the same rank order as the unadjusted rates using site E (the largest site) as the reference. After controlling for SNAP-BP, GA, hypotension, and gender, sites A to D all were significantly less likely to employ vasopressors than sites E or F. After risk adjustment, we found a 43-fold difference between the least aggressive and the most aggressive units (A versus F). Factors, which were insignificant, were race, small for gestational age, and 5-minute Apgar score <7.
In the severe IVH model, after adjustment for the significant contributions of GA and SNAP-BP, the major factor proved to be therapeutic indomethacin treatment (as a proxy for PDA). These babies were 2.5-fold more likely to develop a grade III or IV IVH (95% CI 1.6-3.9). Babies sustaining at least one hypotensive mean BP during the first 12 hours of admission also were 1.6-fold more likely to develop a severe IVH, an OR of borderline significance (95% CI 0.99-2.4). The occurrence of at least one hypertensive mean BP did not contribute to the IVH model (OR of 0.99). Substituting birth weight for GA in this model resulted in hypotension having an OR of 1.7 contributing to the development of a severe IVH (95% CI 1.1-2.7) and hypertension having 0.9 OR (95% CI 0.5-1.5). Being small for gestational age, prophylactic indomethacin, any antenatal steroid, and the 5-minute Apgar score <7 were all non-significant in this model, after adjusting for GA and SNAP.
DISCUSSION
This study examined the differences among six NICUs in the prevalence of extreme BPs (both hypertension and hypotension) and NICU practice styles involving use of vasopressors and volume support. We further examined the association of these and other risk factors with IVH.
We found almost three-fold differences among sites in the odds of hypotension that could not be explained by differences in the populations. Indeed, this may underestimate the true differences among sites because we controlled for antenatal corticosteroid administration, thus reducing the significant advantage in better BPs enjoyed by higher use sites. It appears as if other unmeasured population differences, differences in monitoring or charting technique, or local medical practices are permitting some sites to minimize their incidence of hypotension.
We also found a nearly three-fold unadjusted difference in the incidence of hypertension. We suspect that sites E and F may have targeted higher mean BPs because their use of vasopressors was 5-to 30-fold higher than other sites, even when risk-adjusted for the occurrence of hypotension. In other words, they were likely to administer vasopressors to infants who would not have been considered hypotensive at other sites.
Given these sharp differences in practice style, we evaluated whether either the presence of hypotension or hypertension was risk factor for severe (grade 3 or 4) IVH. After controlling for the highly significant effects of gestational age and initial illness severity, hypotension remained a significant risk factor. The presence of a hypertensive BP was not associated with IVH. We interpret this as supporting the hypothesis of IVH as an ischemic/re-perfusion event rather than a vascular rupture resulting from elevated BP on a pressure-passive cerebral circulation. Supporting this hypothesis are the findings regarding PDA. The occurrence of a PDA (by inference from non-prophylactic indomethacin treatment) increased the odds of IVH by 2.5-fold. That PDA is a risk factor for IVH has been previously reported, 15, 16 and suggests that preventing PDA (such as through prophylactic indomethacin) might reduce the incidence of IVH. These associations among hypotension, PDA, and IVH must be interpreted with caution, however. First, infants who are relatively immature for a given gestation may be more prone to hypotension, PDA, and IVH. Such a relationship would be non-causal because hypotension, PDA, and IVH would each be the result of immaturity. Alternatively, infants who became hypotensive as a result of a PDA could develop sufficient ischemia to cause an IVH. This pathway would be causal (PDA)hypotension)IVH). While one might argue that there could be an association between PDA treatment, indomethacin, and IVH, this is undoubtedly confounding by indication because randomized trials of indomethacin have not indicated a causal link with IVH.
Other approaches to reduce BP fluctuations are narcotics and pancuronium. These have been found to decrease fluctuations of baseline arterial BP 23 and blood flow velocity. 24 -26 The benefits of these in reducing IVH remain unproven. 27 Ultimately, clinical practices should rest on well-conducted, randomized, controlled trials.
We must acknowledge the limitations of our observational study. By design, we recorded only the lowest and highest mean BPs (as components of the SNAP) and the use of therapies including vasopressors and volume support within the first 12 to 24 hours. The study did not take into account the method, the persistence of the hypotension/hypertension, nor the specific timing of these in relation to vasopressors. Because BP measurements were recorded only in the first 12 hours, hypotensive episodes prompting vasopressors may have occurred after the first 12 hours. In addition, we cannot infer whether hypotension occurred and prompted pressor support, whether hypotension occurred despite pressor therapy, or whether proactive use of vasopressors averted hypotension. We are doubtful of this latter hypothesis, as the most aggressive, pressorprone sites had no less hypotension than in the other sites, although this hypotension may have occurred prior to the delivery of vasopressors. A second limitation is the lack of well-established BP standards. For this reason, we replicated our analyses using dataderived quartiles and found identical results. We therefore reported our findings using the standards of Versmold et al. 29 for several reasons: (1) they are widely available, (2) they provide standards for mean BPs, and (3) they are extremely lenient in classifying a wide range of BPs as ''within standard.'' The effect of this lenient classification is that our findings on the statistical and clinical significance of extreme high and low BPs are very conservative. The true effects may be even more substantial. Third, the speed of infusion of volume expansion, which may be a risk factor for IVH, was not a part of this study. Fourth, the process of ascertainment, verification, and recording of hypotension differ among sites. Furthermore, the protocols for initiating vasopressors and recording response to treatment may differ. However, this would highlight the different levels of aggressiveness between NICUs. Finally, we cannot identify whether hypotensive episodes were the result of, rather than an antecedent for, IVH.
In summary, we found large differences in the occurrence of hypotension among six NICUs. We found even larger differences in the aggressiveness of vasopressor administration that could not be explained by birth weight or illness severity or even by the occurrence of hypotension. Among these six NICUs, the risk-adjusted odds of vasopressor use ranged 43-fold. We also found an association between hypotension and IVH, which persisted, at borderline significance, even after adjustment for gestational age, SNAP, and presence of symptomatic PDA (as indicated by prophylactic indomethacin use). This supports a hypotensive ischemic pathogenesis of IVH. However, we found no association between the occurrence of at least one hypertensive episode and IVH. This does not support a hypertensive vascular rupture hypothesis. Severe IVH was also associated with treatment of PDA, which confirms the critical association between PDA and severe IVH.
